Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,581 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urinary Bladder Diseases\Urologic Diseases Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

NCT01953523
View directory record Official record
Conditions
Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions
Administration of autologous adipose derived SVF
Procedure
Lead sponsor
Elliot Lander
Industry
Eligibility
16 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 21, 2026, 4:51 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

NCT06770582
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
145
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 103 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 4:51 PM EDT
Terminated Phase 2 Interventional Results available

Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury

NCT00512148
View directory record Official record
Conditions
Neurogenic Bladder
Interventions
Autologous neobladder construct
Device
Lead sponsor
Tengion
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 21, 2026, 4:51 PM EDT
Completed No phase listed Observational

Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging

NCT00612326
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Carcinoma
Interventions
MRI and PET scanning procedures
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 21, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AQX-1125 in IC/BPS

NCT01882543
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
AQX-1125, Placebo
Drug
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Homewood, Alabama • Glendora, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 21, 2026, 4:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Uro-NIRS Clinical Study

NCT00706407
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder
Interventions
Fully integrated Uro-NIRS:UDS
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 21, 2026, 4:51 PM EDT
Completed Not applicable Interventional Results available

PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB

NCT02857816
View directory record Official record
Conditions
Overactive Bladder
Interventions
NURO System PTNM Therapy
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
St. Petersburg, Florida • Evanston, Illinois • Cambridge, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 21, 2026, 4:51 PM EDT
Recruiting Early Phase 1 Interventional

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

NCT04734106
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Desert Harvest Aloe Vera Capsules, Placebo Capsules
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 21, 2026, 4:51 PM EDT
Terminated Not applicable Interventional

Computer-Assisted Treatment of Urinary Tract Infection in Emergency Departments and Community Health Centers

NCT00731315
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Computer-assisted treatment group, Usual care group
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Fresno, California • Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 4:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 4:51 PM EDT
Recruiting Phase 2 Interventional

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT07285044
View directory record Official record
Conditions
Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
Cancer Therapeutic Procedure, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Fesoterodine Flexible Dose Study

NCT00536484
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Oct 21, 2026, 4:51 PM EDT
Terminated Not applicable Interventional Results available

Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence

NCT03535857
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urinary Incontinence, Urge
Interventions
PTNS
Device
Lead sponsor
Gnankang Sarah Napoe
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 21, 2026, 4:51 PM EDT
Terminated Phase 3 Interventional Results available

4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer

NCT00005047
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2014
U.S. locations
73
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 21, 2026, 4:51 PM EDT
Terminated Phase 2 Interventional Results available

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

NCT00022633
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
92
States / cities
Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 21, 2026, 4:51 PM EDT
Terminated Phase 2 Interventional Results available

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

NCT05581589
View directory record Official record
Conditions
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan
Procedure · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG

NCT02449239
View directory record Official record
Conditions
Bladder Cancer
Interventions
Vicinium
Biological
Lead sponsor
Sesen Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 21, 2026, 4:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder

NCT02745301
View directory record Official record
Conditions
Bladder Cancer, Biomarkers
Interventions
Collection of urine and bladder tumor specimens
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 21, 2026, 4:51 PM EDT
Active, not recruiting Phase 2 Interventional

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

NCT00756639
View directory record Official record
Conditions
Bladder Cancer
Interventions
Prophylactic Cranial Irradiation (PCI), Brain X-ray
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Evaluating the Optimal Volume Voided for Passage of a Backfill-Assisted Voiding Trial Following Urogynecologic Surgery

NCT05820139
View directory record Official record
Conditions
Voiding Dysfunction
Interventions
Control Group, Test Group
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 21, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

NCT01089751
View directory record Official record
Conditions
Overactive Bladder
Interventions
trospium chloride, placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 21, 2026, 4:51 PM EDT
Completed No phase listed Observational

GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology

NCT05470751
View directory record Official record
Conditions
Bladder Outlet Obstruction, Multiple Sclerosis, Cauda Equina Syndrome, Enlarged Prostate With Lower Urinary Tract Symptoms, Parkinson Disease, Lower Urinary Tract Symptoms, Detrusor Underactivity, Spinal Cord Injuries
Interventions
Intermittent self-catheterisation
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
West Orange, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 21, 2026, 4:51 PM EDT
Active, not recruiting Phase 1 Interventional

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04963153
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Enfortumab Vedotin, Erdafitinib, Multigated Acquisition Scan
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

NCT01286454
View directory record Official record
Conditions
Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Interventions
fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 21, 2026, 4:51 PM EDT